Form 4: Veracyte CFO Chambers Acquires Shares from PSU Vesting

Veracyte's Chief Financial Officer, Rebecca Chambers, acquired 59,324 shares of common stock through the vesting of performance-based restricted stock units, subsequently disposing of 12,049 shares for tax obligations.

Summary

• Rebecca Chambers, Chief Financial Officer of Veracyte, Inc. (VCYT), acquired 59,324 shares of common stock on February 26, 2026.
• The acquisition resulted from the vesting of performance-based restricted stock units (PSUs) after the Board of Directors certified the achievement of performance goals.
• Of the vested PSUs, 23,411 shares vested on February 26, 2026, with an additional 35,913 shares scheduled to vest on December 2, 2026, contingent on continuous service.
• Concurrently, 12,049 shares of common stock were disposed of at a price of $38.75 per share to satisfy tax withholding obligations related to the PSU vesting.
• Following these transactions, Rebecca Chambers beneficially owns 156,771 shares of Veracyte, Inc. common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive indicator of management achieving performance targets, although the subsequent tax-related disposition is a neutral, routine event.

Positives

• The vesting of performance-based restricted stock units indicates that the company's Board of Directors certified the achievement of specific performance goals, suggesting positive operational or financial performance.

Negatives

• 12,049 shares were disposed of to cover tax withholding obligations, which is a reduction in direct beneficial ownership, though a standard practice for equity compensation.

Risks

• The vesting of the remaining 35,913 PSUs on December 2, 2026, is subject to Rebecca Chambers' continuous service to the Issuer through that date.

Future Outlook

An additional 35,913 performance-based restricted stock units are scheduled to vest on December 2, 2026, provided the reporting person maintains continuous service to the company until that date.

Industry Context

StockSavvy.ai notes that the vesting of performance-based restricted stock units (PSUs) is a common executive compensation practice across the biotechnology and diagnostics sectors. This mechanism aligns executive incentives with shareholder interests by tying compensation directly to the achievement of specific company performance metrics.

Comparison to Industry Standards

• The use of performance-based restricted stock units (PSUs) as a component of executive compensation is a standard practice within the life sciences and technology industries, comparable to compensation structures at companies like Guardant Health or Exact Sciences.
• The disposition of shares to cover tax obligations upon vesting is also a routine and expected event for equity compensation across all industries, not indicative of unique company-specific issues.

Stakeholder Impact

• Shareholders may view the vesting of PSUs positively as it indicates management's achievement of performance goals, aligning executive incentives with company success.

Next Steps

• The remaining 35,913 performance-based restricted stock units are scheduled to vest on December 2, 2026, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of performance-based restricted stock units and subsequent tax withholding. It does not present new information that would fundamentally alter the investment thesis for Veracyte, Inc., thus a 'hold' recommendation is appropriate.

Keywords

Veracyte, VCYT, Rebecca Chambers, CFO, Form 4, Insider Transaction, Restricted Stock Units, PSUs, Stock Vesting, Tax Withholding, Beneficial Ownership